Boehringer Ingelheim Vetmedica
2015 Revenue: $1.49 billion (€1.36 billion)
HQ: St. Joseph, MO
The closely held Germany-based Boehringer Ingelheim has a strong presence in livestock health but has been looking to branch out into larger markets. In 2015, the company went a long way towards fulfilling that goal, when it announced it will hand over its consumer health business to Sanofi ($SNY) in exchange for No. 4 animal health giant Merial. BI expects that the $12.5 billion asset swap will double its annual animal health sales to €3.8 billion ($4.2 billion). BI was already having a strong year: In 2015, Vetmedica’s sales jumped 10% year-over-year to €1.4 billion ($1.5 billion), as strong demand for its swine vaccine Ingelvac Circoflex pushed sales of that product up 4% to €281 million ($317.9 million). The Merial deal, which is expected to close in 2016, will boost Vetmedica’s profile in companion-animal health, adding such blockbusters as Heartgard and NexGard for controlling parasites in dogs.
Boehringer Ingelheim charts strong growth in livestock meds ahead of Merial union
Sanofi, Boehringer to create new animal health giant in $12.5B asset swap
Boehringer Ingelheim unloads vet plant in Iowa to contract manufacturer